Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Colorectal Neoplasms × Dasatinib × Clear all

Phase

Status

Completed 2 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Recurrence 3 Burkitt Lymphoma 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Chronic-Phase 2 Hematologic Neoplasms 2 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Prostate Cancer Recurrent 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroblastoma 1 Myeloproliferative Disorders 1 Leukemia, Myeloid, Acute 1 Leukemia, Biphenotypic, Acute 1 Leukemia 1 Glioma 1 Glioblastoma 1 Colorectal Neoplasms 1 Blast Crisis 1

Interventions

Bevacizumab 61 Cetuximab 41 Fluorouracil 40 pembrolizumab 31 Oxaliplatin 30 Leucovorin 28 Irinotecan 24 Folfox protocol 20 Specimen Handling 18 Capecitabine 18 HMPL-013 17 Blood Specimen Collection 16 trifluridine tipiracil drug combination 13 Magnetic Resonance Spectroscopy 13 Biopsy 11 regorafenib 10 Trifluridine 10 Panitumumab 10 Gemcitabine 10 Carboplatin 10 Nivolumab 9 IFL protocol 9 Drug Therapy 9 Cisplatin 9 encorafenib 8 Standard of Care 8 Interviews as Topic 8 sintilimab 7 Trastuzumab 7 Radiosurgery 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05725200 2023-02-21

EVIDENT

Oslo University Hospital

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡